Genflow Biosciences Plc, the London-listed biotechnology company, has achieved a significant milestone in its pursuit of longevity research patents.
Genflow Biosciences offers investors exposure to the existing world of longevity and anti-ageing and is one of very few listed longevity pureplays globally.
The firm announced that its licensed patent application for SIRT6 variants has successfully cleared the European Patent Office’s (EPO) supplementary search phase without additional queries.
SIRT6 is a gene recognised for its fundamental role in DNA repair, metabolism, and longevity. The patent’s progression to the national phase represents a crucial advancement in securing European-wide protection for this innovative therapeutic approach.
The patent application, which focuses on preventing and treating age-related diseases through SIRT6 variants, was initially submitted in May 2022 through a collaboration between prestigious American institutions: the University of Rochester, Columbia University, and the Albert Einstein College of Medicine.
The application, filed under number EP 22 808 414.1, has met all requirements set forth by the European Patent Convention. The company now preparing to advance the application ahead of the July 2025 deadline.
“This positive outcome represents a significant step forward in securing broad intellectual property protection for our innovative work on SIRT6 variants,” said Dr. Eric Leire, CEO of Genflow.
“This milestone strengthens our position in SIRT6-based therapeutics and accelerates our mission to develop effective treatments for age-related diseases.”